NL-OMON20549已完成2 期
CareMoreCTC study 2:Activity of trastuzumab based chemotherapy in metastatic breast cancer patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab)
Erasmus MC Cancer Institute, department of Medical Oncology0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Female patient with metastatic breast cancer with HER2-negative primary tumor
- •- Age > 18 years old
排除标准
- •- Previous chemotherapy for metastatic disease.
- •- Adjuvant chemotherapy within 6 months prior to treatment start.
研究者
相似试验
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
已完成
2 期
A Multicenter Phase II study of Trastuzumab emtansine for non-small cell lung cancer positive for HER2 exon 20 insertion mutation.Advanced non-small cell lung cancer positive for HER2 exon 20 insertion mutationJPRN-UMIN000035622Kyushu University Hospital22
招募中
2 期
Phase II single-arm study of Trastuzumab combination with Cisplatin and Gemcitabine as first-line therapy in the HER-2 positive Advanced CholangioCArcinomaAdvanced biliary tract cancersHER-2 positiveFirst-line therapyGallbladder CancerBiliary Tract CancersOncogene Protein HER-2TrastuzumabCisplatinGemcitabineCancer Chemotherapy AgentCombined Antineoplastic AgentsCholangiocarcinomaTCTR20220328005Khon Kaen University33
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45